EMA Ends Year With Set of Straight Noes For PRIME Applicants
Executive Summary
The European Medicines Agency rejected all seven eligibility requests for its priority medicines scheme that it reviewed in December.
You may also be interested in...
PRIME Dry Spell Continues At EMA
Developers of medicines that benefit from the European Medicines Agency’s priority medicines scheme can expect to be eligible for accelerated assessment when they eventually file for approval. But there have been no new entries to the scheme for two months now.
A Whistle-Stop Tour of 2017 – From An EU Regulatory Point Of View
This past year was a busy one for regulators and regulated alike in the EU. We take a look at some of the key events from 2017.
A Whistle-Stop Tour of 2017 – From An EU Regulatory Point Of View
This past year was a busy one for regulators and regulated alike in the EU. We take a look at some of the key events from 2017.